Pro Resolving Mediators : reduce neuro in... - Cure Parkinson's

Cure Parkinson's

25,550 members26,870 posts

Pro Resolving Mediators : reduce neuro inflammation and are easily accessible

7 Replies

I learned of Pro Resolving Mediators from Chris Masterjohn PhD.

Is anyone using Pro Resolving Mediators?

Quote:

“In PD, data suggest SPM are able to cross the blood-brain barrier, inhibit microglial activation and decrease induced markers of inflammation”

ncbi.nlm.nih.gov/pmc/articl...

From what I have read, pro resolving mediators are even more anti-inflammatory than omega 3.

“Acute inflammation is actively terminated by specialized pro-resolving mediators (SPMs) thereby promoting healing and return to homeostasis. Failed resolution may contribute to persistent neuroinflammation and aggravate AD pathology”

pubmed.ncbi.nlm.nih.gov/319...

Read more about...
7 Replies

Just remembered I posted about this before. Whoops. Memory loss at 46. Oh dear. Here is my original post.

healthunlocked.com/cure-par...

Bolt_Upright profile image
Bolt_Upright

Let's beat this up again. I don't think we resolved it last time.

So these are "Specialized Pro-Resolving Lipid Mediators"

Role of Specialized Pro-resolving Mediators in Reducing Neuroinflammation in Neurodegenerative Disorders ncbi.nlm.nih.gov/pmc/articl...

"Minimal data evaluating these PUFA-derived metabolites in humans with neurodegenerative disorders are available and a gap in knowledge exists regarding behavior of SPM and their receptors in patients with these conditions. There is also large gap in our knowledge regarding which SPMs would be most effective in which model of AD or PD and how dietary intake or supplementation can impact SPM levels. Previous work suggests PUFA supplementation may increase plasma levels of lipid-derived mediators in humans under a stressed state (Nordgren et al., 2019). However, there is a current paucity of data regarding baseline SPM levels in patients with neurodegenerative disorders as well as amount of substrate needed to result in a potential clinical improvement. One way to approach these issues is to determine SPM levels in different stages of the disease in both AD and PD, which might be addressed in preclinical or clinical studies. Further, as growing evidence demonstrates overlapping clinical and neuropathologic features of the two conditions, the role of SPM in resolving inflammation in Parkinson’s dementia should also be investigated. As of now, there are no human studies looking into differences in individuals regarding SPM receptor expression or which SPMs would be most helpful to reduce neuroinflammation in AD patients. Furthermore, SPMs affect microglia activation, which can change the course of events from pro-inflammatory to anti-inflammatory depending on the M1/M2 polarization status, and this can lead to neurotoxic or neuroprotective effects. Despite the differences in major symptoms (memory vs. physical), similar issues related to SPMs are also relevant in PD due to the common neuroinflammatory mechanisms. In both diseases, the long-term effects of SPM supplements should be tested to uncover any unfavorable effects or any repair pathways that might be affected by SPM treatment. To the best of our knowledge, there are limited studies investigating the roles of SPMs in AD or PD, and no studies report any adverse effects of SPMs in these disease states. Nevertheless, some studies report that some survival pathways are activated, for example PI3K/Akt survival pathway, which is a pathway that is also implicated in cancers and resistance in cancer therapy. Therefore, the nuances of SPM treatment would need to be defined in AD and PD patients once it acquires clinical use. Large epidemiological studies seeking to understand the effect of diet on SPM levels would be most useful. The ability of SPM to prevent or resolve chronic neuroinflammation may represent a novel approach to treatment. Future direction should include focused, translational efforts to investigate SPM as an add-on (in addition to standard treatment) or as standalone agents in patients with neurodegenerative disorders."

Bolt_Upright profile image
Bolt_Upright in reply to Bolt_Upright

Okay, I am done again. It looks like there is not enough information to add this to my stack. Odd that Life Extensions is cheap and the rest are really expensive.

Agreed. It is going back in my not now, maybe revisit someday file. It’s interesting though.

Different subject, just started a round of activated charcoal for the first time. Timing so as to not mess up absorption of meds and supplements is a challenge.

Smittybear7 profile image
Smittybear7 in reply to

How do you use activated charcoal?

rebtar profile image
rebtar in reply to

Yes! I found it almost impossible to use charcoal separate from meds AND food...my doc suggested two hours after meds and one hour before food...

Bolt_Upright profile image
Bolt_Upright in reply to

Why the activated charcoal? I searched but all I could find was it helps protect the gut when taking antibiotics.

You may also like...

Pro Resolving Mediators : not your typical anti inflammatory. Works via a unique mechanism

by Dr. Chris Masterjohn to help end chronic inflammation. Anyone using pro resolving mediators?...

Reducing oxidative stress and inflammation to slow Parkinson's disease

scientific article with all the source material. Albert...

Inositol hexaphosphate: A natural iron chelator that may protect dopamine neurons

pathways of pro- and anti-inflammatory responses, and resolution of inflammation pathways 2021...

Grounding to reduce inflammation : The Earthing Movie Documentary linked

End Parkinson's Disease. Never hurts to ask.) https://www.youtube.com/watch?v=44ddtR0XDVU

Co Enzyme Q10 & Alpha Lipoic Acid : good anti oxidants or not helpful bad ideas? Do they extend Healthspan or reduce inflammation?

mice” https://pubmed.ncbi.nlm.nih.gov/15059645/ Most anti oxidants don’t extend lifespan...